Status:
COMPLETED
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Vaccines, Pneumococcal
Eligibility:
All Genders
42-98 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with ro...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy 2-month-old infants.
- Available for the entire study period.
- Exclusion criteria:
- · Known contraindication to vaccines.
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
613 Patients enrolled
Trial Details
Trial ID
NCT00366678
Start Date
October 1 2006
End Date
November 1 2008
Last Update
August 15 2012
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Albi, France, 81000
2
Amiens, France, 80000
3
Ancenis, France, 44150
4
Blanquefort, France, 33370